Результаты поиска

Standards of yellow fever vaccination and travel medicine practice in the Republic of Ireland: A questionnaire-based evaluation.

BACKGROUND: The Department of Health regulates the designation of yellow fever vaccination centres (YFVCs) in the Republic of Ireland to ensure appropriate standards in the safe, effective use of yellow fever vaccine for overseas travellers. The process of designation of YFVCs is delegated to Directors of Public Health who direct Principal Medical Officers. Variation in implementation of specific criteria for designation exists and no formal follow up inspection is carried out. This survey of all designated YFVCs in the Republic of Ireland aimed to assess compliance with standards to ensure th…

Defining risk groups to yellow fever vaccine-associated viscerotropic disease in the absence of denominator data.

Several risk groups are known for the rare but serious, frequently fatal, viscerotropic reactions following live yellow fever virus vaccine (YEL-AVD). Establishing additional risk groups is hampered by ignorance of the numbers of vaccinees in factor-specific risk groups thus preventing their use as denominators in odds ratios (ORs). Here, we use an equation to calculate ORs using the prevalence of the factor-specific risk group in the population who remain well. The 95% confidence limits and P values can also be calculated. Moreover, if the estimate of the prevalence is imprecise, discriminati…

Seroprevalence of yellow fever virus in selected health facilities in Western Kenya from 2010 to 2012.

Yellow fever (YF), which is caused by a mosquito-borne virus, is an important viral hemorrhagic fever endemic in equatorial Africa and South America. Yellow fever virus (YFV) is the prototype of the family Flaviviridae and genus Flavivirus. The aim of this study was to determine the seroprevalence of YFV in selected health facilities in Western Kenya during the period 2010-2012. A total of 469 serum samples from febrile patients were tested for YFV antibodies using in-house IgM-capture ELISA, in-house indirect IgG ELISA, and 50% focus reduction neutralization test (FRNT50). The present study d…

How Brazil joined the quest for a yellow fever vaccine. Interview by Claudia Jurberg and Julia D'Aloisio.

Brazil recently announced an agreement between its Bio-Manguinhos vaccine unit and two US companies to research and develop a new yellow fever vaccine. Claudia Jurberg and Julia D'Aloisio talk to Jaime Benchimol about the controversial history of the development of the vaccine that benefits millions of people today.

Immune correlates of protection against yellow fever determined by passive immunization and challenge in the hamster model.

Live, attenuated yellow fever (YF) 17D vaccine is highly efficacious but causes rare, serious adverse events resulting from active replication in the host and direct viral injury to vital organs. We recently reported development of a potentially safer β-propiolactone-inactivated whole virion YF vaccine (XRX-001), which was highly immunogenic in mice, hamsters, monkeys, and humans [10,11]. To characterize the protective efficacy of neutralizing antibodies stimulated by the inactivated vaccine, graded doses of serum from hamsters immunized with inactivated XRX-001 or live 17D vaccine were transf…

Alterations in the Aedes aegypti transcriptome during infection with West Nile, dengue and yellow fever viruses.

West Nile (WNV), dengue (DENV) and yellow fever (YFV) viruses are (re)emerging, mosquito-borne flaviviruses that cause human disease and mortality worldwide. Alterations in mosquito gene expression common and unique to individual flaviviral infections are poorly understood. Here, we present a microarray analysis of the Aedes aegypti transcriptome over time during infection with DENV, WNV or YFV. We identified 203 mosquito genes that were ≥ 5-fold differentially up-regulated (DUR) and 202 genes that were ≥ 10-fold differentially down-regulated (DDR) during infection with one of the three flaviv…

Efficacy of 2'-C-methylcytidine against yellow fever virus in cell culture and in a hamster model.

Yellow fever virus (YFV) continues to cause outbreaks of disease in endemic areas where vaccine is underutilized. Due to the effectiveness of the vaccine, antiviral development solely for the treatment of YFV is not feasible, but antivirals that are effective in the treatment of related viral diseases may be characterized for potential use against YFV as a secondary indication disease. 2'-C-methylcytidine (2'-C-MeC), a compound active against hepatitis C virus, was found to have activity against the 17D vaccine strain of YFV in cell culture (EC(90)=0.32 microg/ml, SI=141). This compound was ef…

Evaluation of yellow fever virus 17D strain as a new vector for HIV-1 vaccine development.

The failure to develop an effective vaccine against HIV-1 infection has led the research community to seek new ways of raising qualitatively different antibody and cellular immune responses. Towards this goal, we investigated the yellow fever 17D vaccine strain (YF17D), one of the most effective vaccines ever made, as a platform for HIV-1 vaccine development. A test antigen, HIV-1 p24 (clade B consensus), was inserted near the 5' end of YF17D, in frame and upstream of the polyprotein (YF-5'/p24), or between the envelope and the first non-structural protein (YF-E/p24/NS1). In vitro characteriza…

[Entomological investigation following the re-emergence of yellow fever in 2008 in Abidjan area (Côte d'Ivoire)].

In April 2008, Abidjan was again faced with another case of yellow fever after the epidemic of 2001 causing mass immunization campaign. In order to evaluate the extent of amaril virus circulation and the risk for local people, an entomological investigation was carried out by the Ministry of Health and Public Hygiene of Côte d'Ivoire. At "Entent" area of Treichville, Breteau index was estimated at 34, recipient index at 20% and house index at 25%. Those indexes were respectively 53, 21 and 31% at "Vridi canal" of Port Bouet. In the both neighborhood, Aedes aegypti accounted for more than 80% o…

Identification and characterization of the catalytic subunit of phosphatidylinositol 3-kinase in the yellow fever mosquito Aedes aegypti.

We characterized the catalytic subunit of phosphatidylinositol 3-kinase in Aedes aegypti (Aaegp110). Aaegp110 is an essential component of the insulin/ insulin growth factor I signaling (IIS) cascade, which regulates aging, reproduction, and other physiological processes in diverse organisms. The Aaegp110 gene encodes five putative domains (adapter binding, ras binding, C2, helical, and PI3-kinase) identified by sequence homology with other p110 proteins. Aaegp110 transcript was expressed during all A. aegypti life stages except late pupae, with particularly high levels in embryos. In female t

Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events.

Since 1996, the scientific community has become aware of 14 reports of yellow fever vaccine (YEL)-associated viscerotropic disease (YEL-AVD) cases and four reports of YEL-associated neurotropic disease (YEL-AND) worldwide, changing our understanding of the risks of the vaccine. Based on 722 adverse event reports after YEL submitted to the U.S. Vaccine Adverse Event Reporting System in 1990-2002, we updated the estimates of the age-adjusted reporting rates of serious adverse events, YEL-AVD and YEL-AND. We found that the reporting rates of serious adverse events were significantly higher among …

Interindividual variation in the response by fibrinogen, C-reactive protein and interleukin-6 to yellow fever vaccination.

The acute phase reaction is important in many disease processes. Habitual levels of the acute phase proteins fibrinogen, C-reactive protein (CRP) and interleukin-6 (IL-6) are associated with an increased risk of cardiovascular disease, but the dynamic variation of plasma levels of acute phase proteins may be of importance as well. The aim of this study was to document the variation in response by fibrinogen, CRP and IL-6 levels to a mild inflammatory stimulus (yellow fever vaccination) in 25 healthy individuals. Plasma levels of fibrinogen, CRP and IL-6 were determined at baseline and 7 days a…

Aedes aegypti в Бразилии: генетически дифференцированные группы населения с высокой степенью подверженности вирусам денге и желтой лихорадки.

Aedes aegypti был исключен из Бразилии в 1955 году, но вновь заразил страну в 1970-х годах. Вспышки денге произошли с 1981 года и стали эндемичными в нескольких городах Бразилии после 1986 года. Желтой лихорадки в городах не было с 1942 года, и сообщалось только о случаях желтой лихорадки в джунглях. На 23 образцах A. aegypti из 13 бразильских штатов был проведен генетический анализ населения с использованием изоэнзима в сочетании с оценкой подверженности как желтой лихорадке, так и вирусу денге 2. Мы продемонстрировали, что экспериментальная инфекция A. aegypti для вирусов денге и желтой лихо

Совпадение в аннотации оригинала
Aedes aegypti was eliminated from Brazil in 1955, but re-infested the country in the 1970s. Dengue outbreaks have occurred since 1981 and became endemic in several cities in Brazil after 1986. Urban yellow fever has not occurred since 1942, and only jungle yellow fever cases have been reported. A population genetic analysis using isoenzyme variation combined…

Vector competence of Brazilian Aedes aegypti and Ae. albopictus for a Brazilian yellow fever virus isolate.

Because the potential urban yellow fever (YF) mosquito vectors Aedes aegypti and Ae. albopictus are at historical highs in Brazil, both in terms of density and geographical range, we assessed the risk of an urban YF epidemic in Brazil. We evaluated and confirmed in a laboratory setting the vector competence of Brazilian Ae. aegypti for a currently circulating strain of YF virus, and investigated the potential for Brazilian Ae. albopictus to transmit YF.

Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two cases.

BACKGROUND: The yellow fever vaccine is regarded as one of the safest attenuated virus vaccines, with few side-effects or adverse events. We report the occurrence of two fatal cases of haemorrhagic fever associated with yellow fever 17DD substrain vaccine in Brazil. METHODS: We obtained epidemiological, serological, virological, pathological, immunocytochemical, and molecular biological data on the two cases to determine the cause of the illnesses. FINDINGS: The first case, in a 5-year-old white girl, was characterised by sudden onset of fever accompanied by headache, malaise, and vomiting 3…

Engineered resistance in Aedes aegypti to a West African and a South American strain of yellow fever virus.

Double subgenomic Sindbis (dsSIN) viruses were engineered to transduce mosquito cells with antisense RNA derived either from the premembrane (prM) or polymerase (NS5) coding regions of the 17D vaccine strain of yellow fever virus (YFV). Aedes albopictus C6/36 cells were infected at high multiplicities of infection (MOI) with each dsSIN virus. Forty-eight hours later, the transduced cells were challenged with an MOI of 0.1 of the Asibi strain of YFV. At 72-hr postchallenge, the cells were assayed by immunofluorescence for the presence of YFV antigen. Cells transduced with prM or NS5 antisense R…

Partial genomic sequence determination of yellow fever virus strain associated with a recent epidemic in Gabon.

A limited epidemic, with important mortality among the initial human cases, occured in a forest region in the north of Gabon by the end of 1994. It was identified as yellow fever according to first serological and reverse transcription/polymerase chain reaction (RT-PCR) results, but no virus was isolated. We received 37 sera from people who lived in the same region and presented symptoms of the disease during the period of concern. In ten of them, we were able to detect and identify yellow fever virus (YFV) RNA by RT-PCR and endonuclease digestion of the RT-PCR products. Nucleotide (nt) sequen…

[The risk of urban yellow fever outbreaks in Brazil by dengue vectors. Aedes aegypti and Aedes albopictus].

Urban yellow fever (YF) epidemics have disappeared from Brazil since about 50 years, but a selvatic cycle still exist. In many States, cases are more or less numerous each year. Ae. aegypti was eradicated in 1954, re-appeared temporarily in 1967, and then definitively in 1976-1977. Ae. aegypti is a vector of yellow few (YF), but also of dengue, whose first cases were reported in 1982. Today, dengue is endemic in many regions. A second Flavivirus vector, Aedes albopictus is present since about ten years in some States, from which Säo Paulo. The analysis of the YF cases between 1972 and 1994 all…

A factor Xa-directed anticoagulant from the salivary glands of the yellow fever mosquito Aedes aegypti.

Salivary gland extracts from the yellow fever mosquito Aedes aegypti contain a factor Xa-specific anticoagulant detectable in vitro by clotting assays. The anticoagulant is found only in female salivary glands, which is consistent with its role in bloodfeeding. Extracts of adult female glands significantly delay both the prothrombin time and the activated partial thromboplastin time, but have no effect on the thrombin clotting time. The anticoagulant has been shown to result from the specific inhibition of coagulation factor Xa based on a FXa clotting assay and the inhibition of FXa-directed c…

Human antibodies to dengue and yellow fever do not react in diagnostic assays for hepatitis C virus.

Hepatitis C virus (HCV) is a recently described causative agent of the great majority of post-transfusion non A-non B hepatitis and is classified within the Flaviviridae family. Due to a high prevalence of anti-HCV and other flaviviruses circulating in Brazil, such as dengue and yellow fever, we investigated the possibility of serological cross-reactivity between these viruses. Different panels of human sera positive for dengue type 1 (9 cases) and type 2 (7 cases) from 6 patients naturally infected with yellow fever and from 94 adults vaccinated against the 17D strain of yellow fever were tes…